Mediaboss Marketing

After a year in which scientists raced to understand Covid-19 and to develop treatments and vaccines to stop its spread, Cleveland Clinic is partnering with IBM to use next-generation technologies to advance healthcare research and potentially prevent the next public health crisis.

The two organizations on Tuesday announced the creation of the "Discovery Accelerator," which will apply technologies such as quantum computing and artificial intelligence to pressing life sciences research questions. As part of the partnership, Cleveland Clinic will become the first private-sector institution to buy and operate an on-site IBM quantum computer, called the Q System One. Currently, such machines only exist in IBM labs and data centers.

Quantum computing is expected to expedite the rate of discovery and help tackle problems with which existing computers struggle.

The accelerator is part of Cleveland Clinic's new Global Center for Pathogen Research & Human Health, a facility introduced in January on the heels of a $500 million investment by the clinic, the state of Ohio and economic development nonprofit JobsOhio to spur innovation in the Cleveland area.

The new center is dedicated to researching and developing treatments for viruses and other disease-causing organisms. That will include some research on Covid-19, including why it causes ongoing symptoms (also called "long Covid") for some who have been infected.

"Covid-19 is an example" of how the center and its new technologies will be used, said Dr. Lara Jehi, chief research information officer at the Cleveland Clinic.

"But ... what we want is to prevent the next Covid-19," Jehi told CNN Business. "Or if it happens, to be ready for it so that we don't have to, as a country, put everything on hold and put all of our resources into just treating this emergency. We want to be proactive and not reactive."

Quantum computers process information in a fundamentally different way from regular computers, so they will be able to solve problems that today's computers can't. They can, for example, test multiple solutions to a problem at once, making it possible to come up with an answer in a fraction of the time it would take a different machine.

Applied to healthcare research, that capability is expected to be useful for modeling molecules and how they interact, which could accelerate the development of new pharmaceuticals. Quantum computers could also improve genetic sequencing to help with cancer research, and design more efficient, effective clinical trials for new drugs, Jehi said.

Ultimately, Cleveland Clinic and IBM expect that applying quantum and other advanced technologies to healthcare research will speed up the rate of discovery and product development. Currently, the average time from scientific discovery in a lab to getting a drug to a patient is around 17 years, according to the National Institutes of Health.

"We really need to accelerate," Jehi said. "What we learned with the Covid-19 pandemic is that we cannot afford, as a human race, to just drop everything and focus on one emergency at a time."

Part of the problem: It takes a long time to process and analyze the massive amount of data generated by healthcare, research and trials something that AI, quantum computing and high-performance computing (a more powerful version of traditional computing) can help with. Quantum computers do that by "simulating the world," said Dario Gil, director of IBM Research.

"Instead of conducting physical experiments, you're conducting them virtually, and because you're doing them virtually through computers, it's much faster," Gil said.

For IBM, the partnership represents an important proof point for commercial applications of quantum computing. IBM currently offers access to quantum computers via the cloud to 134 institutions, including Goldman Sachs and Daimler, but building a dedicated machine on-site for one organization is a big step forward.

"What we're seeing is the emergency of quantum as a new industry within the world of information technology and computing," Gil said. "What we're seeing here in the context of Cleveland Clinic is ... a partner that says, 'I want the entire capacity of a full quantum computer to be [dedicated] to my research mission."

The partnership also includes a training element that will help educate people on how to use quantum computing for research which is likely to further grow the ecosystem around the new technology.

Cleveland Clinic and IBM declined to detail the cost of the quantum system being installed on the clinic's campus, but representatives from both organizations called it a "significant investment." Quantum computers are complex machines to build and maintain because they must be stored at extremely cold temperatures (think: 200 times colder than outer space).

The Cleveland Clinic will start by using IBM's quantum computing cloud offering while waiting for its on-premises machine to be built, which is expected to take about a year. IBM plans to later install at the clinic a more advanced version of its quantum computer once it is developed in the coming years.

Jehi, the Cleveland Clinic research lead, acknowledged that quantum computing technology is still nascent, but said the organization wanted to get in on the ground floor.

"It naturally needs nurturing and growing so that we can figure out what are its applications in healthcare," Jehi said. "It was important to us that we design those applications and we learn them ourselves, rather than waiting for others to develop them."

Read more:
Cleveland Clinic and IBM hope their tech partnership could help prevent the next pandemic - WTHITV.com

Quantum Computing Market is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. This analysis provides an examination of various market segments that are relied upon to observe the fastest development amid the estimated forecast frame. The report encompasses market definition, currency and pricing, market segmentation, market overview, premium insights, key insights and company profile of the key market players. The persuasive Quantum Computing market report also helps to know about the types of consumers, their response and views about particular products, and their thoughts for the step up of a product.

Quantum computing is an advanced developing computer technology which is based on the quantum mechanics and quantum theory. The quantum computer has been used for the quantum computing which follows the concepts of quantum physics. The quantum computing is different from the classical computing in terms of speed, bits and the data. The classical computing uses two bits only named as 0 and 1, whereas the quantum computing uses all the states in between the 0 and 1, which helps in better results and high speed. Quantum computing has been used mostly in the research for comparing the numerous solutions and to find an optimum solution for a complex problem and it has been used in the sectors like chemicals, utilities, defence, healthcare & pharmaceuticals and various other sectors. Quantum computing is used for the applications like cryptography, machine learning, algorithms, quantum simulation, quantum parallelism and others on the basis of the technologies of qubits like super conducting qubits, trapped ion qubits and semiconductor qubits. Since the technology is still in its growing phase, there are many research operations conducted by various organizations and universities including study on quantum computing for providing advanced and modified solutions for different applications. For instance, Mercedes Benz has been conducting research over the quantum computing and how it can be used for discovering the new battery materials for advanced batteries which can be used in electric cars. Mercedes Benz has been working in collaboration with the IBM on IBM Q network program, which allows the companies in accessing the IBMs Q network and early stage computing systems over the cloud. Global quantum computing market is projected to register a healthy CAGR of 29.5% in the forecast period of 2019 to 2026.

Download Sample Copy of the Report to understand the structure of the complete report (Including Full TOC, Table & Figures) @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-quantum-computing-market&Somesh

Quantum Computing Market Scope and Segmentation:

Global quantum computing market is segmented into seven notable segments which are system, qubits, deployment model, component, application, logic gates and vertical.

Quantum Computing Market Country Level Analysis

For detailed insights on Global Quantum Computing Market Size, competitive landscape is provided i.e. Revenue Share Analysis (Million USD) by Players, Revenue Market Share (%) by Players and further a qualitative analysis is made towards market concentration rate, product differentiation, new entrants are also considered in heat map concentration.

New Business Strategies, Challenges & Policies are mentioned in Table of Content, Request TOC at @https://www.databridgemarketresearch.com/toc/?dbmr=global-quantum-computing-market&Somesh

Leading Key Players Operating in the Quantum Computing Market Includes:

Some of the major players operating in this market are Honeywell International, Inc., Accenture, Fujitsu, Rigetti & Co, Inc., 1QB Information Technologies, Inc., IonQ, Atom Computing, ID Quantique, QuintessenceLabs, Toshiba Research Europe Ltd, Google,Inc., Microsoft Corporation, Xanadu, Magiq Technologies, Inc., QX branch, NEC Corporation, Anyon System,Inc. Cambridge Quantum Computing Limited, QC Ware Corp, Intel Corporation and others.

Product Launch

The Quantum Computing Market research covers a comprehensive analysis of the following facts:

Table of Content:

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: INTRODUCTION

PART 05: MARKET LANDSCAPE

PART 06: MARKET SIZING

PART 07: FIVE FORCES ANALYSIS

PART 08: MARKET SEGMENTATION BY PRODUCT

PART 09: MARKET SEGMENTATION BY DISTRIBUTION CHANNEL

PART 10: CUSTOMER LANDSCAPE

PART 11: MARKET SEGMENTATION BY END-USER

PART 12: REGIONAL LANDSCAPE

PART 13: DECISION FRAMEWORK

PART 14: DRIVERS AND CHALLENGES

PART 15: MARKET TRENDS

PART 16: COMPETITIVE LANDSCAPE

PART 17: COMPANY PROFILES

PART 18: APPENDIX

Inquire Before Buying This Research Report:https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-quantum-computing-market&Somesh

About Us:

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with an unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to complex business challenges and initiates an effortless decision-making process.

Contact:

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

corporatesales@databridgemarketresearch.com

Read the rest here:
Quantum Computing Market Share Current and Future Industry Trends, 2020 to 2027 The Courier - The Courier

BRUSSELS Johnson & Johnson said Tuesday that it would resume the rollout of its coronavirus vaccine in Europe after the European Unions drug regulator said that a warning should be added to the product indicating a possible link to rare blood clots, but that the shots benefits outweigh the risks.

The company decided to delay distribution in the blocs 27 member states last week, after regulators in the United States suspended use of the vaccine there amid concerns about the potential side effect.

The E.U. drug regulators endorsement even with the caveat not only clears a path for Johnson & Johnson in Europe, but could presage how the United States will handle the vaccine in the days to come.

On Friday, an advisory panel to the Centers for Disease Control and Prevention is to meet for a second to time to decide whether to recommend lifting a pause put on the vaccines use in the United States, perhaps with a similar warning.

That would free up millions of doses for a country still waging a fierce battle against the pandemic, and where almost eight million Americans have already had the Johnson & Johnson vaccine.

But some health experts worry that the headline-grabbing pause, which began over a week ago, might discourage some people from getting vaccinated, even though the risks from Covid-19 are far greater than the risk from a clot.

Youve put a scarlet letter on the Johnson & Johnson vaccine, said Dr. Paul A. Offit, a vaccine expert at Childrens Hospital of Philadelphia.

After clotting concerns associated with another vaccine, produced by AstraZeneca, were reported in Europe, Dr. Offit noted, some grew leery of it, overestimating the threat. For the Johnson & Johnson vaccine, the clot risk has been put at an estimated one in a million.

If you take a theoretical million people who are infected with Covid, five thousand will die, Dr. Offit said. Therefore, the benefits of this vaccine clearly outweigh its risks.

A loss of confidence in the Johnson & Johnson vaccine may carry a particular cost.

The vaccine has been greeted warmly by many health workers because it requires just a single shot, unlike the ones from Moderna or Pfizer-BioNTech, and is easier to store than some other vaccines. It is especially useful for hard-to-reach or transient populations.

There is no doubt in my mind that there are groups for whom this vaccine is of benefit, Dr. Offit said, meaning that theyre more likely to get this vaccine than the other vaccines, whether its because of where they live, or because theyre homebound, or its hard to get a second dose.

If that changes, he said, then you have probably elevated a rare risk above a much more common risk, and youve done harm.

In clearing the way for the vaccines use, the E.U.s drug regulator, the European Medicines Agency, said the blood clots, which have been reported in a very small group of people, are very similar to those associated with the AstraZeneca vaccine.

The E.M.A.s recommendation is not binding, but it is the first indication of what might happen next with the European rollout of the Johnson & Johnson vaccine.

April 25, 2021, 10:32 a.m. ET

The agency said that authorities in individual E.U. member states should decide how to proceed, taking into account their particular case load and vaccine availability. Poland is the only E.U. country that defied the companys guidance and went ahead and administered some Johnson & Johnson doses over the past week.

All the rare cases of blood clots reviewed by the European regulator were reported in the United States, but the agency proceeded with its recommendations Tuesday before U.S. regulators acted.

Europe has been here before.

In early March, regulators began receiving reports of rare blood clots in Europeans who had been vaccinated with the AstraZeneca shot, which has been widely used on the continent. E.U. and national regulators then scrambled to interpret and respond to the findings.

The E.U. regulator said it had moved faster in greenlighting the Johnson & Johnson vaccine than the U.S. authorities have because, having spent the past two months reviewing the AstraZeneca issues, it had built some confidence in how to respond.

In a statement, the agency stressed the importance of treating the potential side effect and issued guidelines to health care professionals on the lookout for the rare clotting disorder. It listed symptoms to be vigilant for, including shortness of breath, chest pain, leg swelling, persistent abdominal pain, severe and persistent headaches or blurred vision, and tiny blood spots under the skin.

The temporary suspension of the Johnson & Johnson rollout in the European Union had added to the blocs vaccine rollout woes, but it was not as big a blow as the AstraZeneca issues have been.

Vaccination efforts have fallen behind in Europe partly because AstraZeneca, a British-Swedish pharmaceutical company that is a major component of the regions inoculation efforts, was unable to deliver the number of doses expected in the first quarter of the year. Then its vaccine was suspended over the blood-clotting concerns.

Even though the authorities eventually declared that the benefits of the AstraZeneca vaccine outweighed risks, and advised E.U. members to use it, the damage had been done.

Many Europeans have been refusing to take it, and several E.U. countries have limited its use to older people, as most of those affected by the rare clots were younger than 60.

Confronted with supply shortages after the AstraZeneca and the Johnson & Johnson disruptions, the European Union last week announced it was increasing its supply of the Pfizer-BioNTech vaccine, and was negotiating a new deal for future booster shots with the company for 2022 and 2023.

But while the impact for Europe may be cushioned, it could be a different story elsewhere. The Johnson & Johnson vaccine has been an important component of vaccination plans for countries around the world.

While it has not yet been rolled out at anything near the scale of AstraZenecas, some regions have pivoted to the shot amid AstraZeneca shortages. The African Union recently acquired 400 million doses.

The pause on Johnson & Johnson vaccinations in the United States, along with new restrictions on the use of AstraZenecas shot in Europe, rattled vaccination campaigns around the world relying on those vaccines. South Africa followed the United States in pausing Johnson & Johnson shots, though its health regulator in recent days recommended resuming its use.

U.S. health officials called for a pause in the vaccines use on April 13. Johnson & Johnson suspended its E.U. rollout immediately afterward, just as the first shipments of the shot were arriving in the region.

U.S. regulators and scientists are still studying the original reports of the clotting disorder and sifting through any new safety reports of possible cases of the clotting disorder. That effort has so far turned up little.

Dr. Rochelle P. Walensky, the C.D.C. director, said on Monday that health officials were investigating a handful of new, unconfirmed reports that emerged after the pause was recommended, to determine whether they might be cases of the rare blood clotting disorder.

Right now, we are encouraged that it hasnt been an overwhelming number of cases, but we are looking and seeing what has come in, she said at a White House news conference.

Carl Zimmer contributed reporting from New Haven; Noah Weiland and Sharon LaFraniere from Washington; and Benjamin Mueller from London.

See the original post:
Johnson & Johnson to Resume European Union Vaccine Rollout - The New York Times

The European Union put forward a package of measures that took aim at the patchy data available around sustainable investing, seen as one of the fast-growing markets biggest problems.

The blocs executive arm in Brussels proposed making companies for the first time report standardized information about their impact on their environment, and social metrics, such as how they treat their employees.

The EU wants the rules to apply to both publicly-listed firms in Europe and large private companies, a total of nearly 50,000 entities. Credit institutions, including the large U.S. banks that have subsidiaries in the EU, would also have to comply. The bloc also unveiled its classification system that will define green investments, and said the taxonomy will apply from next year.

If passed, companies in the EU will have to start disclosing sustainability metrics, similarly to financial reporting. The taxonomy is expected to be used as a tool to cut down on greenwashing, a term that describes an exaggeration of sustainability claims. The initial version of the taxonomy labels bioenergy as green, but doesnt include nuclear energy and natural gas, although this may be revised.

Sustainability has emerged as a hot topic in finance. It is commonly known by the acronym ESG, which stands for environmental, social and governancethree pillars on which companies are judged.

Follow this link:
European Union Aims for Clarity in Murky World of Sustainable Investing - The Wall Street Journal

The European Union has committed to very significant emission cuts 55% on 1990 levels by 2030, and zero net emissions by 2050.

To help it get there without too much disruption, the president of the European Commission proposed a carbon tariff known as the carbon border adjustment mechanism, or CBAM.

The details will be tabled in the European Parliament later this year.

A carbon tariff is a tax on imports based on the carbon dioxide emissions involved in making them. Its purpose is to level the playing field with the domestic producers who will be made to pay a carbon price based on their emissions.

At the Victoria University Centre of Policy Studies we have modelled the effect on Australias economy.

Initially, we find it will reduce demand for Australian exports of coal, and steel and other emissions-intensive commodities, lowering both export prices and volumes.

But then a range of second round effects will kick in.

Lower export income will lower the Australian dollar, pushing up prices for Australian households, particularly the price of imports.

The lower dollar will also make exporters not directly affected by CBAM more attractive to customers overseas.

How big will these effects be?

We have used simulations from the Victoria University Regional Model to run the numbers taking into account emissions intensities, the importance of the EU as a destination for individual Australian exports and the extent to which Australian producers are able to divert each export from the EU to other markets.

Increase in price of exports to EU under carbon border adjustment mechanism

We find that some of the price effects are big (especially for coal) but, with a few exceptions, the EU isnt an important market for Australian exports.

The exceptions are steel, alumina and aluminium where the EU accounts for between 10% and 20% of Australias exports.

Our simulations suggest that for the most part that the projected impacts on the Australian economy are small.

The long-run projected loss in gross domestic product is 0.05%, which is equivalent to a fall in weekly income of less than $1 per person or about one weeks worth of normal growth.

At an industry level, most industries slightly increase production, the fall in EU demand being more than compensated for by the weaker exchange rate.

Following a temporary increase in unemployment, job losses in declining industries are offset by expansion in other industries.

Change in industry output under carbon border adjustment mechanism

The main loser is coal mining. The carbon border adjustment mechanism has the potential to increase the landed duty-paid price of Australian-produced coal in the EU by more than half, effectively excluding it from the EU market.

Overall, it is projected to cut Australian coal production by 3.8% relative to where it would have been with the loss of about 3,000 jobs.

The mechanism is projected to increase the buying price of iron and steel in the EU by almost 10%. While the EU is an important export market for Australian iron and steel, most of it is sold within Australia, meaning total production should fall by only 0.6%.

The decline in production should be relatively small, costing around 200 jobs.

Read more: The EU is considering carbon tariffs on Australian exports. Is that legal?

The job losses in mining and metal industries would be offset by the gains in the other industries which are able to take advantage of the lower exchange rate, including agriculture, some parts of manufacturing, tourism and education.

A temporary increase in unemployment as workers transition out of affected industries could be eased by training and other support for displaced workers.

Excerpt from:
Australia's economy can withstand the proposed European Union carbon tariff here's what we find - The Conversation AU